Kamada Ltd. KMDA
At closeNov 9, 2026, 4:14 AM EST
Pre-market · Nov 9, 4:14 AM ET
- YTD
- +2.41%
- 1 year
- +9.21%
- Market cap
- 417.25M
- Revenue (ttm)
- 154.57M
- Profit margin
- 9.75%
- EPS (ttm)
- 0.38
- Shares out
- 57.49M
- P/E ratio
- 19.03
- Forward P/E
- 19.52
- Dividend yield
- 1.73%
- YTD return
- +2.41%
- 1-year return
- +9.21%
- Volume
- 101.84K
- Avg volume
- 136.83K
- Open
- 6.99
- Previous close
- 6.87
- Day's range
- 6.99 – 7.27
- 52-week range
- 6.60 – 9.35
- Beta
- 0.20
- Price target
- 14.67 (+102.9%)
5D -0.30 (-3.98%)
Key statistics
- Enterprise value
- 276.22M
- PEG ratio
- 0.00
- Price / sales
- 2.33
- Price / book
- 1.43
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 13.40%
- Free cash flow
- -7.77M
- Total cash
- 56.55M
- Total debt
- 8.56M
- Return on equity
- 7.04%
- Short % of float
- 0.09%
- 50-day average
- 5.77
- 200-day average
- 5.52
Analyst view
- Target (low)
- 11.00
- Target (mean)
- 14.67
- Target (high)
- 20.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.06.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.07 | 0.07 | 0.00 | 0.00% |
| Aug 14, 2024 | Jun 1, 2024 | 0.06 | 0.08 | +0.02 | +33.33% |
| May 8, 2024 | Mar 1, 2024 | 0.06 | 0.04 | -0.02 | -33.33% |
| Mar 6, 2024 | Dec 1, 2023 | 0.05 | 0.09 | +0.04 | +80.00% |
| Nov 13, 2023 | Sep 1, 2023 | 0.03 | 0.06 | +0.03 | +100.00% |
| Aug 16, 2023 | Jun 1, 2023 | 0.02 | 0.04 | +0.02 | +100.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 3, 2024 | Stifel | init | — | Buy |
| May 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 14, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Kamada Ltd.
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Israel
- Website
- kamada.com
News
Your note
Sign in to keep a note on KMDA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Phoenix Holdings Ltd. | 3.19% | 1,832,952 | 11.09M | Sep 29, 2024 |
| Vanguard Group Inc | 2.41% | 1,384,430 | 8.38M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.49% | 856,106 | 5.18M | Sep 29, 2024 |
| Y.D. More Investments Ltd | 1.23% | 709,551 | 4.29M | Sep 29, 2024 |
| Wells Fargo & Company | 1.10% | 629,884 | 3.81M | Sep 29, 2024 |
| Millennium Management Llc | 0.62% | 354,776 | 2.15M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard International Stock Index-Total Intl Stock Indx | 1.13% | 650,238 | 3.93M | Jul 30, 2024 |
| Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 0.54% | 308,828 | 1.87M | Sep 29, 2024 |
| DFA Continental Small Company Series | 0.35% | 203,071 | 1.23M | Jul 30, 2024 |
| Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index | 0.26% | 146,585 | 886.84K | Jul 30, 2024 |
| DFA International Core Equity Portfolio | 0.14% | 78,512 | 475.00K | Jul 30, 2024 |
| Schwab Strategic Tr-Schwab International Small Cap Equity ETF | 0.13% | 73,700 | 445.88K | Aug 30, 2024 |